Lack of interaction between cimetidine and buspirone.
Simultaneous administration of cimetidine and many benzodiazepine anxiolytics has resulted in decreased body clearance and marked prolongation of the half-life of these agents. The pharmacokinetic interaction of buspirone, a new nonbenzodiazepine anxiolytic, and cimetidine was studied in 10 healthy male volunteers. Each received, in order, buspirone 45 mg/day (days 1-7), no drug (days 8-14), cimetidine 1 g/day (days 15-21), buspirone 45 mg/day plus cimetidine 1 g/day (days 22-28), and cimetidine 1 g/day (days 29-31). Buspirone and 1-pyrimidinyl piperazine (1-PP), an active metabolite, pharmacokinetics, urinary excretion of cimetidine, a manual dexterity test, the Stroop color-word interference test, and a visual analog mood scale were evaluated on each treatment. There were no significant (p greater than 0.05) differences among treatments for any measurement except for a slight (31%) but significant (p less than 0.05) increase in the 1-PP Cmax value. These results suggest that within the normal therapeutic dosage ranges for both drugs, it is unlikely that a clinically significant interaction between them will occur.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000378:metabolism*; D002065:Buspirone / Q000031:analogs & derivatives; D002927:Cimetidine / Q000009:adverse effects / Q000494:pharmacology* / Q000652:urine; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D010879:Piperazines / Q000378:metabolism; D011597:Psychomotor Performance / Q000187:drug effects; D011743:Pyrimidines / Q000009:adverse effects / Q000378:metabolism*
D014151:Anti-Anxiety Agents; D010879:Piperazines; D011743:Pyrimidines; D002927:Cimetidine; C037921:1-(2-pyrimidinyl)piperazine; D002065:Buspirone